LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior

Abstract

Background: Uterine corpus endometrial carcinoma (UCEC) is one of the most common gynecological malignancies and its incidence and mortality continue apace. Lysosome-associated membrane protein 3 (LAMP3) is the third member of the LAMP family and its overexpression has been described to be involved in the progression of breast, ovarian and cervical cancers, but there has been an absence of research focusing on its role in UCEC. Methods: WGCNA, TIMER, LinkedOmics, GSEA, Cytoscape, Kaplan-Meier plotter, GDC, GeneMANIA, cBioPortal, PDB, RNAinter, miRNet were applied in this research. Results: Our study uncovers that LAMP3 possesses higher expression levels in UCEC compared to normal tissues, and this differential expression profile is tightly aligned with clinical and pathological features, and patients demonstrating high LAMP3 expression tend to have a shorter survival expectancy. The high expression of LAMP3 is modulated by the designated ceRNA network. LAMP3 is engaged in UCEC progression by functioning in a variety of biological roles of relevance to immunity. Furthermore, we predicted several prospering drugs based on drug sensitivity. Finally, we also constructed possible docking patterns of LAMP3 with ABCA3, RAB9A, and SGTB. Conclusions: LAMP3 is a formidable biomarker for UCEC and could be a prospective candidate for the diagnosis, treatment and prognostic assessment of UCEC.

Independent organelle and organelle—organelle interactions: essential mechanisms for malignant gynecological cancer cell survival

“…Expression of mitochondria-related molecules and OXPHOS affect endometrial cancer cell migration, invasion, disease severity, and prognosis ( 72 – 75 ); regulation of mitochondria is thus a primary way to induce apoptosis in endometrial cancer treatment ( 76 – 80 ). Expressions of many lysosomal and ER biogenic genes and factors affect endometrial cancer prognosis, effectively predict immune associations, and can be used as biomarkers ( 81 , 82 , 84 , 85 , 87 ). Thus, the diversity of organelle genes and factors diversify potential endometrial cancer treatment approaches.…”

“…This is primarily regulated by a specific ceRNA network, the differential expression profile of which is closely associated with clinical and pathological features. Patients exhibiting high LAMP 3 expression tend to have shorter survival expectancies, making it a potent UCEC biomarker and potential diagnosis, treatment, and prognostic assessment candidate ( 85 ).…”